GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immunotech Biopharm 6978.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.38

0.00%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Immunotech Biopharm

Its shares trade on HKEX under the ticker 6978.HK. It has been listed since 10 July 2020.

Immunotech Biopharm Ltd. operates as an investment holding company, which through its subsidiaries engages in research and development, manufacturing and commercialization of immune cell products for treatments of cancers in the PRC. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-07-10. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. The company also provides cell cryopreservation services. The firm mainly conducts its businesses in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
10 Jul 2020
Employees
203
Website
eaal.net ↗

Leadership

Pay as last reported

  • Mr. Zheng TanExecutive Chairman of the Board, since 2018CN¥10.6m
  • Dr. Yu WangChief Executive Officer, Chief Technology Officer, Executive Director, since 2019CN¥37.6m
  • Mr. Jian ZhangSenior Vice President
  • Mr. Yu ZhangChief Scientist
  • Ms. Shui Bing LeungJoint Company Secretary, since 2024
  • Mr. Ran TaoNon-Executive Director
  • Mr. Donghu WangNon-Executive Director
  • Mr. Ruihua WangNon-Executive Director
  • Mr. Fan YangNon-Executive Director
  • Mr. Chi Kit NgNon-Executive Independent DirectorCN¥249,000
  • Ms. Sujiu PengNon-Executive Independent DirectorCN¥252,000
  • Prof. Yingdian WangNon-Executive Independent DirectorCN¥252,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Immunotech Biopharm Ltd. develops EAL, a multi-target cellular immunotherapy product in the PRC.
  • The company's CAR-T cell series and TCR-T cell series products target cancer treatments in China.
  • Immunotech Biopharm Ltd. offers cell cryopreservation services as part of its biotechnology services.

Weaknesses

  • Immunotech Biopharm Ltd. operates solely in the domestic market within the PRC.
  • The company has only 203 employees, which may limit its operational scale.
  • Immunotech Biopharm Ltd. is listed on the domestic market with no international presence.

Opportunities

  • The growing demand for cancer treatments in China presents a significant market opportunity.
  • Expansion of immune cell product applications could increase market share in the PRC.
  • Increasing investment in biotechnology research may boost Immunotech Biopharm Ltd.'s R&D capabilities.

Threats

  • Competition from other biotechnology firms in the PRC could impact market share.
  • Regulatory changes in the Chinese healthcare sector may affect operations.
  • Economic downturns in China could reduce demand for cancer treatments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.